Zhifei Biological (智飞生物)

Zhifei Biological Tetanus Vaccine Enters Phase I/III Trials

Zhifei Biological has announced that its adsorbed tetanus vaccine has advanced into Phase I/III clinical trials. This marks a significant step in the development of a new vaccine, potentially impacting the company's future product pipeline and market position in the infectious disease sector.

Zhifei Biological Receives Approval for DTaP-Hib Vaccine

Zhifei Biological announced the approval of its adsorbed acellular DTaP-Hib vaccine. This vaccine combines protection against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b. The approval signifies an expansion of Zhifei's pediatric vaccine portfolio, aiming to provide comprehensive immunization against common childhood diseases.

Zhifei Biological's Combined Vaccine Enters Phase I Clinical Trials

Zhifei Biological has announced that its adsorbed acellular DTaP (component) and Haemophilus influenzae type b (conjugate) combined vaccine has entered Phase I clinical trials. This marks a significant step in the development of a new combination vaccine, potentially expanding Zhifei's product pipeline and market offerings in the pediatric vaccine segment.

Zhifei Biological Secures New Vaccine Technology Patent

Zhifei Biological has announced the acquisition of a new invention patent certificate, indicating advancements in its vaccine research and development capabilities. This patent could strengthen its intellectual property portfolio and potentially lead to new product offerings or improved existing ones, offering a positive outlook for its technological competitiveness.

Chengan Bio Receives Approval for Degludec Aspart Insulin Injection

Zhifei Biological's controlling subsidiary, Chengan Bio, has secured marketing approval for its Degludec Aspart Insulin Injection. This combination insulin product offers a new therapeutic option for managing diabetes. The approval underscores Chengan Bio's ongoing efforts to diversify its insulin product line and meet patient needs.

Chengan Bio's Dual Receptor Agonist Approved for Metabolic Diseases

Zhifei Biological's controlling subsidiary, Chengan Bio, has received approval for its GLP-1/GIP dual receptor agonist. This innovative drug targets metabolic diseases, offering a new therapeutic avenue. The approval underscores Chengan Bio's commitment to developing advanced treatments for chronic conditions.

Chengan Bio Insulin Injection Approved by Zhifei Biological Subsidiary

Zhifei Biological's controlling subsidiary, Chengan Bio, has received approval for its Degludec Insulin Injection. This marks a significant step in expanding its diabetes treatment portfolio. The approval is based on the product's quality and efficacy, aiming to provide patients with advanced therapeutic options.